Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
454 studies found for:    "Gliosarcoma"
Show Display Options
Rank Status Study
1 Active, not recruiting DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors
Condition: Glioblastoma or Gliosarcoma
Interventions: Drug: Single intratumoral injection of DNX-2401;   Drug: Interferon-gamma
2 Completed
Has Results
Avastin in Combination With Temozolomide for Unresectable or Multifocal GBMs and Gliosarcomas
Conditions: Glioblastoma;   Gliosarcoma
Intervention: Drug: Avastin and Temozolomide
3 Withdrawn Phase II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma
Conditions: Glioblastoma;   Gliosarcoma
Interventions: Drug: Temozolomide;   Radiation: Radiation;   Drug: Sorafenib
4 Completed Phase I Portion of Phase I/II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma
Conditions: Glioblastoma;   Gliosarcoma
Interventions: Drug: Temozolomide;   Radiation: Radiation;   Drug: Sorafenib
5 Completed
Has Results
Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma
Conditions: Glioblastoma;   Gliosarcoma
Interventions: Drug: Bevacizumab;   Drug: Tarceva;   Drug: Temozolomide
6 Recruiting NU-0129 in Treating Patients With Recurrent Glioblastoma or Gliosarcoma Undergoing Surgery
Conditions: Gliosarcoma;   Recurrent Glioblastoma
Interventions: Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Targeted Molecular Therapy
7 Completed Phase 1/2 Study in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients
Conditions: Glioblastoma;   Glioblastoma Multiforme;   Gliosarcoma
Interventions: Drug: enzastaurin;   Drug: temozolomide;   Radiation: radiation
8 Unknown  Study of AR-67 in Adult Patients With Recurrence of Glioblastoma Multiforme (GBM) or Gliosarcoma
Conditions: Glioblastoma Multiforme;   GBM;   Gliosarcoma
Intervention: Drug: AR-67 (7-t-butyldimethylsiltyl-10-hydroxy-camptothecin)
9 Completed
Has Results
Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and Gliosarcomas
Conditions: Glioblastoma;   Gliosarcoma;   Brain Tumor
Interventions: Drug: Avastin;   Drug: Temozolomide;   Radiation: Radiation Therapy (XRT);   Drug: Irinotecan
10 Recruiting BPM31510 in Treating Patients With Recurrent Glioblastoma or Gliosarcoma Previously Treated With Bevacizumab
Conditions: Gliosarcoma;   Recurrent Glioblastoma
Interventions: Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Ubidecarenone Injectable Nanosuspension
11 Recruiting Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
Conditions: Gliosarcoma;   Supratentorial Glioblastoma
Interventions: Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Drug: Temozolomide
12 Completed
Has Results
Avastin/Temozolomide/Irinotecan for Unresectable/Multifocal Glioblastoma Multiforme
Conditions: Glioblastoma Multiforme;   Gliosarcoma
Interventions: Drug: Avastin;   Drug: Temozolomide;   Drug: Irinotecan
13 Completed
Has Results
Safety and Efficacy Study of Tarceva, Temodar, and Radiation Therapy in Patients With Newly Diagnosed Brain Tumors
Conditions: Glioblastoma Multiforme;   Gliosarcoma
Interventions: Drug: Tarceva;   Drug: Temodar;   Procedure: Radiation Therapy
14 Completed Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
Conditions: Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma;   Recurrent Adult Brain Tumor
Interventions: Drug: sorafenib tosylate;   Drug: erlotinib hydrochloride;   Drug: tipifarnib;   Drug: temsirolimus
15 Active, not recruiting Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma
Conditions: Giant Cell Glioblastoma;   Glioblastoma;   Gliosarcoma
Interventions: Biological: bevacizumab;   Drug: temozolomide;   Other: laboratory biomarker analysis;   Other: immunohistochemistry staining method;   Genetic: microarray analysis;   Genetic: DNA methylation analysis
16 Completed
Has Results
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
Conditions: Adult Glioblastoma;   Adult Gliosarcoma;   Recurrent Adult Brain Tumor
Interventions: Drug: irinotecan hydrochloride;   Biological: bevacizumab;   Drug: temozolomide
17 Completed Tipifarnib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
Conditions: Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma
Interventions: Drug: tipifarnib;   Drug: temozolomide;   Radiation: radiation therapy
18 Completed
Has Results
Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
Conditions: Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma
Interventions: Radiation: 3-dimensional conformal radiation therapy;   Drug: temozolomide;   Drug: motexafin gadolinium
19 Terminated
Has Results
Erlotinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
Condition: Adult Brain Tumors
Intervention: Drug: erlotinib hydrochloride
20 Enrolling by invitation Evaluation Of The Treatment Effectiveness Of Glioblastoma / Gliosarcoma Through The Suppression Of The PI3K/Akt Pathway In Compared With MK-3475
Condition: Glioblastoma
Interventions: Drug: MK - 3475;   Biological: Suppressor of the PI3K/Akt pathways

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.